Shah Iftikhar Ali, Memon Mubeen, Ansari Sheeba, Kumar Ratan, Chandio Sultan A, Mirani Shahid H, Rizwan Amber
Internal Medicine, Ghulam Muhammad Mahar Medical College and Hospital, Sukkur, PAK.
Pulmonology, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.
Cureus. 2021 Feb 4;13(2):e13137. doi: 10.7759/cureus.13137.
Coenzyme Q10 (CoQ10) has a potential role in reducing the risk of myocardial infarction by slowing the progression of atherosclerosis and improving ischemia. In this study, we will assess the role of coenzyme Q10 in prophylaxis for reducing myocardial infarction and mortality related to myocardial infarction.
This open-label two open placebo-controlled randomized clinical trial was conducted in a tertiary care hospital in Sukkur, Pakistan from April 2016 to September 2019. Eight hundred nighty-two (892) patients with clinically diagnosed and documented evidence of hypertension were enrolled in the study from the outpatient department. Participants were randomized into two groups by 1:1 ratio using an online randomizer software, Research Randomizer (https://www.randomizer.org/). Group A received 100 mg coenzyme Q10 daily (coenzyme Q10 group) in addition to standard therapy and group B received standard therapy only (placebo group).
Participants who received coenzyme Q10 had fewer incidence of non-fatal myocardial infarction over 12 months (5.4% vs 8.4%) with relative risk reduction of 2.92 (confidence interval 95%, 0.55-2.76). The number needed to treat to prevent one non-fatal myocardial infarction was 34. Participants who received coenzyme Q10 had fewer incidence of fatal myocardial infarction over 12 months (1.5% vs 3.1%) with relative risk reduction of 1.65 (confidence interval 95%, 0.39-3.69). Number needed to treat to prevent one fatal myocardial infarction was 60.
According to this study, coenzyme Q10 reduced the incidence of fatal and non-fatal myocardial infarctions. Clinicians should consider adding coenzyme Q10 to the treatment regimen of high-risk patients of myocardial infarction. We suggest coenzyme Q10 may be an effective prophylactic agent in patients at risk of myocardial infarction and it may help in reducing burden on the health care system.
辅酶Q10在减缓动脉粥样硬化进展和改善缺血方面具有降低心肌梗死风险的潜在作用。在本研究中，我们将评估辅酶Q10在预防心肌梗死及降低与心肌梗死相关死亡率方面的作用。
这项开放标签的双盲安慰剂对照随机临床试验于2016年4月至2019年9月在巴基斯坦苏库尔的一家三级护理医院进行。从门诊部招募了892例临床诊断并有高血压记录证据的患者。使用在线随机软件Research Randomizer（https://www.randomizer.org/）按1:1比例将参与者随机分为两组。A组在标准治疗基础上每日服用100毫克辅酶Q10（辅酶Q10组），B组仅接受标准治疗（安慰剂组）。
接受辅酶Q10的参与者在12个月内非致命性心肌梗死的发生率较低（5.4%对8.4%），相对风险降低2.92（95%置信区间，0.55 - 2.76）。预防一例非致命性心肌梗死所需治疗人数为34。接受辅酶Q10的参与者在12个月内致命性心肌梗死的发生率较低（1.5%对3.1%），相对风险降低1.65（95%置信区间，0.39 - 3.69）。预防一例致命性心肌梗死所需治疗人数为60。
根据本研究，辅酶Q10降低了致命性和非致命性心肌梗死的发生率。临床医生应考虑在心肌梗死高危患者的治疗方案中添加辅酶Q10。我们建议辅酶Q10可能是心肌梗死风险患者的一种有效预防药物，它可能有助于减轻医疗保健系统的负担。
